
ML Strategies
Viewpoints
Filter by:
Post-Election 2022: A Look into the Next Congress
November 22, 2022 | Blog | By Anthony DeMaio, Pamela Mejia
Energy & Sustainability Washington Update — October 2022
October 4, 2022 | Article | By R. Neal Martin
Webinar: The Inflation Reduction Act - Are You Ready?
August 19, 2022 | Webinar | By Anne S. Levin-Nussbaum, R. Neal Martin
“Commercial Surveillance” Questions Take Center Stage at the Federal Trade Commission
August 18, 2022 | Blog | By Michael Goldberg, Cynthia Larose
ML Strategies Outlook: Federal Action Post-Dobbs Decision
July 25, 2022 | Blog | By Pamela Mejia, Ellen Janos, Kaitlyn Sprague
Look Ahead: Upcoming Congressional Work Period – July 2022
July 11, 2022 | Blog | By Alexander Hecht, Christian Tamotsu Fjeld, Anthony DeMaio, R. Neal Martin, Pamela Mejia
The next three weeks will be full of activity in Washington D.C., as the House of Representatives and Senate are working to push their legislative agendas to garner support from their constituents ahead of an August recess and before political “silly season” officially kicks in ahead of the upcoming mid-term elections in November. Here’s our latest update on what you can expect in Congress during the July work period.
Read more
Understanding the American Data Privacy and Protection Act
June 8, 2022 | Blog | By Christian Tamotsu Fjeld, Cynthia Larose
Massachusetts Information Security and Privacy Act Sent to “Study”
June 2, 2022 | Blog | By Cynthia Larose, Daniel Connelly
Summer 2022 Is Here – Do You Know How the FDA User Fee Legislation Is Going?
June 2, 2022 | Blog | By Joanne Hawana
Anyone who has spent any time around health care policymaking circles in Washington, D.C. has heard about the intense five-year cycle Congress goes through in order to reauthorize the biggest user fee programs at the Food and Drug Administration (FDA). Mintz previously published this wonderful explanation of the process complete with an estimated timeline for how this year’s reauthorization was likely to go. As a reminder, the current authorization for FDA’s various human product user fee programs – with the exception of the over-the-counter drug program that was freshly created in 2020 – will expire on September 30, 2022 with the end of the federal government’s fiscal year, unless they are renewed by Congress before that time.
Read more
ML Strategies Energy & Sustainability Washington Update - June 2022
May 31, 2022 | Blog | By R. Neal Martin
Massachusetts for ARPA-H
May 3, 2022 | Blog | By Anthony DeMaio
ML Strategies Energy & Sustainability Washington Update — May 2022
April 29, 2022 | Blog | By R. Neal Martin
ML Strategies Energy & Sustainability Washington Update — April 2022
March 30, 2022 | Blog | By R. Neal Martin
ML Strategies Energy & Sustainability Washington Updates - March 2022
February 25, 2022 | Blog | By R. Neal Martin
Major Update in Data Privacy Laws Proposed in Massachusetts
February 3, 2022 | Blog | By Daniel Connelly, Kaitlyn Sprague, Taylor Shepherd
On February 2, 2022, the Massachusetts Legislature’s Joint Committee on Advanced Information Technology, the Internet and Cybersecurity released a new draft of a bill designed to provide mechanisms for how personal information is used and to control how companies use such information. This 65-page bill, known as the “Massachusetts Information Privacy and Security Act” or “MIPSA”, would be the first major piece of legislation related to data privacy passed since the Legislature updated the data breach legislation in 2019.
Read more
ML Strategies Energy & Sustainability Washington Update — February 2022
January 31, 2022 | Blog | By R. Neal Martin
Governor Baker Releases Eighth Budget Recommendation
January 26, 2022 | Blog | By Daniel Connelly, Kaitlyn Sprague, Taylor Shepherd
Today, Governor Charlie Baker released his Fiscal Year 2023 (FY2023) budget recommendations. This is the unofficial start of “budget season” in Massachusetts that will culminate with a legislative conference committee agreeing on a budget bill sometime around late June or early July.
Read more
Snapshot of Another Much-Too-Busy Year for FDA Before 2022 Really Gets Started
January 5, 2022 | Blog | By Joanne Hawana , Benjamin Zegarelli
It is, somewhat amazingly, the beginning of January again. During this time of year we typically publish a series of blog posts that recap the most interesting Food and Drug Administration (FDA) activities over the prior 12 months and consider what the agency is likely to focus on going forward. This year, however, we’re taking a different approach and will be providing more of a birds-eye view of our favorite federal agency as it stands as of the end of 2021. Because there is just too much going on at the administrative, enforcement, and legislative levels to get into the details of everything in one fell swoop. So make sure you’re signed up for Mintz Health Law Viewpoints to receive updates throughout the year on issues as they develop.
Read more
FDA Issues Draft Device Guidance in Preparation for the End of the Public Health Emergency
December 27, 2021 | Blog | By Benjamin Zegarelli
On December 22, 2021, FDA took another step in rolling back enforcement policies implemented in response to the COVID-19 pandemic by publishing guidance documents describing the regulatory requirements for devices that were authorized under the emergency use authorization process and those under temporary FDA policies implementing specific enforcement discretion during the pandemic once the Public Health Emergency for COVID-19 ends. The Transition Plan Guidances will help device manufacturers prepare for the end of the PHE and continue to commercialize devices necessary for the long-term response to COVID-19.
Read more
Explore Other Viewpoints:
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Cross-Border Asset Recovery
- Debt Financing
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment, Labor & Benefits
- Energy & Sustainability
- Environmental Enforcement Defense
- Environmental Law
- FDA Regulatory
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- Strategic IP Monetization & Licensing
- Tax
- Technology
- Technology, Communications & Media
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology